Screening Libraries

PARG-IN-4

Cat. No.: HY-156881 2988890-20-4 CAS No.: Molecular Formula: $C_{20}H_{25}F_{2}N_{7}O_{2}S_{2}$

Molecular Weight: 497.59

Poly(ADP-ribose) Glycohydrolase (PARG) Target:

Pathway: Cell Cycle/DNA Damage

Storage: Powder -20°C 3 years

2 years -80°C 6 months

In solvent

-20°C 1 month

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 20 mg/mL (40.19 mM; ultrasonic and warming and heat to 80°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.0097 mL	10.0484 mL	20.0969 mL
	5 mM	0.4019 mL	2.0097 mL	4.0194 mL
	10 mM	0.2010 mL	1.0048 mL	2.0097 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2 mg/mL (4.02 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2 mg/mL (4.02 mM); Clear solution; Need ultrasonic
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2 mg/mL (4.02 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

PARG-IN-4 (Formula (A)) is an orally active and cell-permeable PARG inhibitor. PARG-IN-4 effectively inhibits tumor growth in mouse models. PARG-IN-4 can be used in cancer research^[1].

REFERENCES

1]. Paul A Barsanti, et al. Piperazine substituted indazole compounds as inhibitors of parg. Patent WO2023183850A1.							
			lical applications. For research use				
	Tel: 609-228-6898 Address: 1 De	Fax: 609-228-5909 eer Park Dr, Suite Q, Monmou	E-mail: tech@MedChemExpressith Junction, NJ 08852, USA	s.com			

Page 2 of 2 www.MedChemExpress.com